Evidence map›Paper›PMID 33694069›Full record

ArticleFamilial cancer2022

Age of diagnosis in familial Barrett's associated neoplasia.

Benita K Glamour, Omar Alaber, Gino Cioffi, Apoorva K Chandar, Jill Barnholtz-Sloan, Wendy Brock, Gary W Falk, Marcia I Canto, Jean S Wang, Prasad G Iyer and 6 more

Open access · greenAbstract read
In one paragraph

Article in Familial cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Improving outcomes in patients with oesophageal cancer.Nature reviews. Clinical oncology · 2023
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 1 country.

Benita K GlamourCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Omar AlaberUniversity Hospitals - Cleveland Medical Center, Cleveland, OH, USA.
Gino CioffiDepartment of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Apoorva K ChandarUniversity Hospitals - Cleveland Medical Center, Cleveland, OH, USA.
Jill Barnholtz-SloanDepartment of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Wendy BrockUniversity Hospitals - Cleveland Medical Center, Cleveland, OH, USA.
Gary W FalkHospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Marcia I CantoJohns Hopkins Hospital, Baltimore, MD, USA.
Jean S WangWashington University School of Medicine, St. Louis, MO, USA.
Prasad G IyerMayo Clinic, Rochester, MN, USA.
Nicholas J ShaheenUniversity of North Carolina, Chapel Hill, NC, USA.
William M GradyUniversity of Washington Medical Center, Seattle, WA, USA.
Julian A AbramsColumbia University Medical Center, New York, NY, USA.
Prashanthi N ThotaCleveland Clinic Foundation, Cleveland, OH, USA.
Amitabh Chak *Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Andrew E Blum *Case Western Reserve University School of Medicine, Cleveland, OH, USA. Andrew.blum@case.edu.
University Hospitals of Cleveland · USCase Western Reserve University · USCase Comprehensive Cancer CenterCleveland Clinic · USColumbia University Irving Medical Center · USHospital of the University of Pennsylvania · USJohns Hopkins Hospital · USMayo Clinic in Arizona · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington Medical Center · USUniversity School · USWashington University in St. Louis · US

Funding

Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6M
Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
The Case Medical Student Summer Research Program (MSSRP)T35DK111373 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Fabio Cominelli, Theresa Torres Pizarro · 2016 to 2026
$718k
TGFβ and Smad Signaling Components in Esophageal AdenocarcinomaIK2CX001831 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI Andrew Edward Blum · 2020 to 2026
–
CSRD VA IK2 CX001831NCI NIH HHS P50 CA150964NCI NIH HHS U54 CA163060NIDDK NIH HHS T35 DK111373
6 · The paper itself

Abstract

The identification of hereditary cancer genes for esophageal adenocarcinoma (EAC) and its precursor, Barrett's esophagus (BE), may prove critical for the development of novel prevention and treatment strategies. Specifically, efforts for detecting BE and EAC susceptibility genes have focused on families with three or more affected members, since these individuals have an earlier age onset compared to non-familial individuals. Given that the use of BE may overestimate the likelihood of disease heritability, we evaluated the age of diagnosis in kindreds with a restricted definition including only confirmed high-grade dysplasia (HGD) or EAC. The Familial Barrett's Esophagus Consortium database was used to identify individuals with HGD and EAC. These individuals were subsequently split into three kindred groups: non-familial-a single affected family member, duplex-two affected family members, and multiplex-three or more affected family members. Age of cancer diagnosis and other risk factors were compared between individuals in these groups. The study included 441 non-familial, 46 duplex, and 13 multiplex individuals. There was a statistically significant difference for age of diagnosis for individuals in the multiplex families compared to the non-familial and duplex families (56.0 versus 64.3, 63.5; p = 0.049). There was no significant difference between demographic factors and other cancer risk factors between family types. The results of this study support a genetic basis for familial Barrett's associated neoplasia and evaluation of the genetic susceptibility to this disease should continue to focus on families with multiple (three or more) affected members.

Indexed as

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsNeoplastic Syndromes, HereditaryHumansRisk FactorsBarrett’s associated neoplasiaBarrett’s esophagusEsophageal adenocarcinomaFamilial Barrett’s esophagus

Identifiers

PMID33694069
PMCPMC9469732
OpenAlexW3134984431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.